Top

Journal of Assisted Reproduction and Genetics

Published in:

Open Access 01-12-2019 | Fertility | Fertility Preservation

Counseling young women with early breast cancer on fertility preservation

Authors: M. E. (Elena) ter Welle-Butalid, I. J. H. (Ingeborg) Vriens, J. G. (Josien) Derhaag, E. M. (Edward) Leter, C. E. (Christine) de Die-Smulders, M. (Marjolein) Smidt, R. J. T. (Ron) van Golde, V. C. G. (Vivianne) Tjan-Heijnen

Published in: Journal of Assisted Reproduction and Genetics | Issue 12/2019

Abstract

Purpose

Women with early-stage breast cancer may still have a future child wish, while chemotherapy may impair fertility. To pursue on fertility preservation shortly after breast cancer diagnosis is complex. This review holds a critical reflection on all topics that need to be counseled to give them the opportunity to make a well-informed decision before starting any oncological treatment.

Methods

A comprehensive literature review was performed on papers published in English language on breast cancer in young women, risk of chemotherapy-induced infertility, fertility preservation techniques, impact of possible mutation carriership, and future pregnancy outcome.

Results

Below 40 years of age, the risk of permanent chemotherapy-induced ovarian function failure is approximately 20%, where taxanes do not significantly add to this risk. Overall, 23% of reported women who performed fertility preservation by cryopreserving oocytes or embryos returned for embryo transfer. Of these, 40% gave live birth. Both fertility preservation in women diagnosed with breast cancer and pregnancy after treatment seem safe with respect to breast cancer survival. Women who have a genetic predisposition for breast cancer like BRCA gene mutation should also be informed about the possibility of pre-implantation genetic diagnosis.

Conclusions

Women with an early stage of breast cancer and a possible future child wish should be referred to an expertise center in breast cancer, fertility preservation, and genetics in this complex decision-making process, shortly after diagnosis.

Ferlay L, Soerjomataram I, Ervik M. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer (GLOBOCAN), 2012. http://globocan.iarc.fr. Accessed 11 March 2017.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–30. https://doi.org/10.1200/JCO.2007.14.2471.CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005;365(9472):1687–717. https://doi.org/10.1016/s0140-6736(05)66544-0.CrossRef

Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early-stage breast cancer. Fertil Steril. 2010;94(2):638–44. https://doi.org/10.1016/j.fertnstert.2009.03.045.CrossRefPubMed

Mathews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief. 2009;21:1–8.

Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160–70. https://doi.org/10.1093/annonc/mdt199.CrossRefPubMed

Oktay K, Harvey BE, Partridge A, Quinn G, Reinecke J, Taylor HS, Hamish Wallace W, Wang ET, Loren AW. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018:1-8. doi:https://doi.org/10.1200/JCO10.1200/JCO.2018.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet. 2012;379(9814):432–44. https://doi.org/10.1016/s0140-6736(11)61625-5.CrossRef

Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;23(12):2716–25. https://doi.org/10.1200/JCO.2005.06.178.CrossRefPubMed

10.

Fiets WE. Prognostication and treatment decision-making in early breast cancer. Dissertation, University of Leiden, the Netherlands, 2006.

11.

Goldfarb SB, Kamer SA, Oppong BA, Eaton A, Patil S, Junqueira MJ, et al. Fertility preservation for the young breast cancer patient. Ann Surg Oncol. 2016;23:1530–6. https://doi.org/10.1245/s10434-015-5036-8.CrossRefPubMedPubMedCentral

12.

Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–83. https://doi.org/10.1200/JCO.2004.01.159.CrossRefPubMed

13.

Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging. 2011;3(8):782–93. https://doi.org/10.18632/aging.100363.CrossRefPubMedPubMedCentral

14.

Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, et al. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol: RB&E. 2010;8:20. https://doi.org/10.1186/1477-7827-8-20.CrossRef

15.

Yucebilgin MS, Terek MC, Ozsaran A, Akercan F, Zekioglu O, Isik E, et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Austral New Zealand J Obstet Gynaecol. 2004;44(1):6–9. https://doi.org/10.1111/j.1479-828X.2004.00143.x.CrossRef

16.

Bar-Joseph H, Stemmer SM, Tsarfaty I, Shalgi R, Ben-Aharon I. Chemotherapy-induced vascular toxicity--real-time in vivo imaging of vessel impairment. J Vis Exp. 2015;95:e51650. https://doi.org/10.3791/51650.CrossRef

17.

Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31. https://doi.org/10.1200/JCO.2006.06.5888.CrossRefPubMed

18.

Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1. https://doi.org/10.1186/s12916-015-0545-7.CrossRefPubMedPubMedCentral

19.

Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045–51. https://doi.org/10.1200/JCO.2005.03.3969.CrossRefPubMed

20.

Vriens IJ, De Bie AJ, Aarts MJ, de Boer M, van Hellemond IE, Roijen JH, et al. The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. Oncotarget. 2017;8(7):11372–9. https://doi.org/10.18632/oncotarget.14532.CrossRefPubMedPubMedCentral

21.

Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791–8. https://doi.org/10.1002/cncr.24835.CrossRefPubMed

22.

Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer. 2010;116(13):3102–11. https://doi.org/10.1002/cncr.25106.CrossRefPubMed

23.

Yoo C, Yun MR, Ahn JH, Jung KH, Kim HJ, Kim JE, et al. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. Cancer Chemother Pharmacol. 2013;72(3):565–75. https://doi.org/10.1007/s00280-013-2227-5.CrossRefPubMed

24.

Narmadha MP, Malaikkal V, Rajendran NN. Assessment of chemotherapy induced amenorrhea (CIA) in hormone receptor positive premenopausal women with breast cancer. Res J Pharmaceut Biol Chem Sci. 2012;3(4):97–106.

25.

Berliere M, Dalenc F, Malingret N, Vindevogel A, Piette P, Roche H, et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer. 2008;8:56. https://doi.org/10.1186/1471-2407-8-56.CrossRefPubMedPubMedCentral

26.

Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009;115(2):335–42. https://doi.org/10.1007/s10549-008-0071-9.CrossRefPubMed

27.

Zhou W, Ding Q, Liang X, He Z, Zha X, Liu X, et al. The risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy. PLoS One. 2012;7(5):e37249. https://doi.org/10.1371/journal.pone.0037249.CrossRefPubMedPubMedCentral

28.

Okanami Y, Ito Y, Watanabe C, Iijima K, Iwase T, Tokudome N, et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182–8. https://doi.org/10.1007/s12282-011-0256-7.CrossRefPubMed

29.

van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, et al. Ovarian function recovery during anastrozole in breast cancer patients with chemotherapy-induced ovarian function failure. J Natl Cancer Inst. 2017;109(12). https://doi.org/10.1093/jnci/djx074.

30.

Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24(36):5769–79. https://doi.org/10.1200/JCO.2006.07.2793.CrossRefPubMed

31.

Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol. 2009;27(19):3192–7. https://doi.org/10.1200/jco.2008.18.6213.CrossRefPubMed

32.

Regan MM, Walley BA, Francis PA, Fleming GF, Lang I, Gomez H, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Annals of Oncology. 2017;28(9):2225–32.CrossRef

33.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2013;381(9869):805–16. https://doi.org/10.1016/s0140-6736(12)61963-1.CrossRef

34.

Berger JC, Clericuzio CL. Pierre Robin sequence associated with first trimester fetal tamoxifen exposure. Am J Med Genet A. 2008;146A(16):2141–4. https://doi.org/10.1002/ajmg.a.32432.CrossRefPubMed

35.

Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99(2):477–83. https://doi.org/10.1016/j.fertnstert.2012.09.039.CrossRefPubMed

36.

Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew K, Lobo RA, et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer. 2010;116(9):2099–105. https://doi.org/10.1002/cncr.25037.CrossRefPubMedPubMedCentral

37.

Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007;96(12):1808–16. https://doi.org/10.1038/sj.bjc.6603814.CrossRefPubMedPubMedCentral

38.

Rosendahl M, Andersen CY, La Cour FN, Juul A, Lossl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril. 2010;94(1):156–66. https://doi.org/10.1016/j.fertnstert.2009.02.043.CrossRefPubMed

39.

Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008;26(3):286–95. https://doi.org/10.1080/07357900701829777.CrossRefPubMedPubMedCentral

40.

Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006;21(10):2583–92. https://doi.org/10.1093/humrep/del201.CrossRefPubMed

41.

Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist. 2014;19(1):68–74. https://doi.org/10.1634/theoncologist.2013-0145.CrossRefPubMed

42.

Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer. 2013;49(16):3404–11. https://doi.org/10.1016/j.ejca.2013.07.014.CrossRefPubMedPubMedCentral

43.

Hamy AS, Porcher R, Eskenazi S, Cuvier C, Giacchetti S, Coussy F, et al. Anti-Mullerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies. Reprod Biomed Online. 2016;32(3):299–307. https://doi.org/10.1016/j.rbmo.2015.12.008.CrossRefPubMed

44.

Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26–36. https://doi.org/10.1093/humupd/dms041.CrossRefPubMed

45.

Tal R, Seifer DB, Wantman E, Baker V, Tal O. Antimullerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. Fertil Steril. 2018;109(2):258–65. https://doi.org/10.1016/j.fertnstert.2017.10.021.CrossRefPubMed

46.

van Tilborg TC, Oudshoorn SC, Eijkemans MJC, Mochtar MH, van Golde RJT, Hoek A, et al. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. Hum Reprod. 2017;32(12):2485–95. https://doi.org/10.1093/humrep/dex321.CrossRefPubMed

47.

Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ, Marjoribanks J, Torrance H, Broekmans FJ. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) (Review). Cochrane Database of Systematic Reviews 2018, Issue 2. https://doi.org/10.1002/14651858.CD012693.pub2.

48.

Chien AJ, Chambers J, McAuley F, Kaplan T, Letourneau J, Hwang J, et al. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017;165(1):151–9. https://doi.org/10.1007/s10549-017-4288-3.CrossRefPubMed

49.

Garcia-Velasco JA, Domingo J, Cobo A, Martinez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99(7):1994–9. https://doi.org/10.1016/j.fertnstert.2013.02.004.CrossRefPubMed

50.

Michaan N, Ben-David G, Ben-Yosef D, Almog B, Many A, Pauzner D, et al. Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients. Eur J Obstet Gynecol Reprod Biol. 2010;149(2):175–7. https://doi.org/10.1016/j.ejogrb.2009.12.023.CrossRefPubMed

51.

Robertson AD, Missmer SA, Ginsburg ES. Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril. 2011;95(2):588–91. https://doi.org/10.1016/j.fertnstert.2010.04.028.CrossRefPubMed

52.

Babb A, Farah N, Lyons C, Lindsay K, Reddy N, Goldman J, et al. Uptake and outcome of assisted reproductive techniques in long-term survivors of SCT. Bone Marrow Transplant. 2012;47(4):568–73. https://doi.org/10.1038/bmt.2011.134.CrossRefPubMed

53.

Sabatini ME, Wolkovich AM, Macklin EA, Wright DL, Souter I, Toth TL. Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients. J Assist Reprod Genet. 2011;28(3):279–84. https://doi.org/10.1007/s10815-010-9515-3.CrossRefPubMed

54.

Barcroft J, Dayoub N, Thong KJ. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. Journal of Assisted Reproduction and Genetics. 2013;30(11):1407–13. https://doi.org/10.1007/s10815-013-0024-z.CrossRefPubMedPubMedCentral

55.

Courbiere B, Decanter C, Bringer-Deutsch S, Rives N, Mirallie S, Pech JC, et al. Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study. Hum Reprod. 2013;28(9):2381–8. https://doi.org/10.1093/humrep/det268.CrossRefPubMed

56.

Dolmans MM, Hollanders de Ouderaen S, Demylle D, Pirard C. Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment. Journal of Assisted Reproduction and Genetics. 2015;32(8):1233–7. https://doi.org/10.1007/s10815-015-0533-z.CrossRefPubMedPubMedCentral

57.

Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33(22):2424–9. https://doi.org/10.1200/jco.2014.59.3723.CrossRefPubMedPubMedCentral

58.

Hammarberg K, Kirkman M, Stern C, McLachlan RI, Clarke G, Agresta F, et al. Survey of reproductive experiences and outcomes of cancer survivors who stored reproductive material before treatment. Hum Reprod. 2017;32(12):2423–30. https://doi.org/10.1093/humrep/dex314.CrossRefPubMed

59.

Moravek MB, Confino R, Smith KN, Kazer RR, Klock SC, Lawson AK, et al. Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil Steril. 2018;109(2):349–55. https://doi.org/10.1016/j.fertnstert.2017.10.029.CrossRefPubMedPubMedCentral

60.

Cardozo ER, Thomson AP, Karmon AE, Dickinson KA, Wright DL, Sabatini ME. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience. J Assist Reprod Genet. 2015;32(4):587–96. https://doi.org/10.1007/s10815-015-0428-z.CrossRefPubMedPubMedCentral

61.

Yang D, Brown SE, Nguyen K, Reddy V, Brubaker C, Winslow KL. Live birth after the transfer of human embryos developed from cryopreserved oocytes harvested before cancer treatment. Fertil Steril. 2007;87(6):1469 e1461–4. https://doi.org/10.1016/j.fertnstert.2006.07.1546.CrossRef

62.

Dahhan T, Dancet EA, Miedema DV, van der Veen F, Goddijn M. Reproductive choices and outcomes after freezing oocytes for medical reasons: a follow-up study. Hum Reprod. 2014;29(9):1925–30. https://doi.org/10.1093/humrep/deu137.CrossRefPubMed

63.

Martinez M, Rabadan S, Domingo J, Cobo A, Pellicer A, Garcia-Velasco JA. Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer. Reprod Biomed Online. 2014;29(6):722–8. https://doi.org/10.1016/j.rbmo.2014.09.002.CrossRefPubMed

64.

Diaz-Garcia C, Domingo J, Garcia-Velasco JA, Herraiz S, Mirabet V, Iniesta I, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018. https://doi.org/10.1016/j.fertnstert.2017.11.018.CrossRef

65.

Meneses K, Holland AC. Current evidence supporting fertility and pregnancy among young survivors of breast cancer. J Obstet Gynecol Neonatal Nurs. 2014;43(3):374–81. https://doi.org/10.1111/1552-6909.12301.CrossRefPubMed

66.

Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47(1):74–83. https://doi.org/10.1016/j.ejca.2010.09.007.CrossRefPubMed

67.

Hack KE, Derks JB, Elias SG, Franx A, Roos EJ, Voerman SK, et al. Increased perinatal mortality and morbidity in monochorionic versus dichorionic twin pregnancies: clinical implications of a large Dutch cohort study. BJOG. 2008;115(1):58–67. https://doi.org/10.1111/j.1471-0528.2007.01556.x.CrossRefPubMed

68.

Ell K, Nishimoto R, Mantell J, Hamovitch M. Longitudinal analysis of psychological adaptation among familiy members of patients with cancer. J Psychosom Res. 1988;32(4/5):429–38.CrossRef

69.

Brandao T, Schulz MS, Matos PM. Psychological intervention with couples coping with breast cancer: a systematic review. Psychol Health. 2014;29(5):491–516. https://doi.org/10.1080/08870446.2013.859257.CrossRefPubMed

70.

Dolmans MM, Lambertini M, Macklon KT, Santos TA, Ruiz-Casado A, Borini A, et al. European Recommendations for female FERtility preservation (EU-REFER): a joint collaboration between oncologists and fertility specialists. Crit Rev Oncol Hematol Jun. 2019;138:233–40. https://doi.org/10.1016/j.critrevonc.2019.03.010.CrossRef

71.

Cobo A, Garcia-Velasco JA, Coello A, Domingo J, Pellicer A, Remohi J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755–64. https://doi.org/10.1016/j.fertnstert.2015.11.027.CrossRefPubMed

72.

Donnez J, Dolmans MM. Fertility preservation in Women. N Engl J Med. 2004;377(17):1657–65. https://doi.org/10.1056/NEJMra1614676.CrossRef

73.

Sánchez-Serrano M, Crespo J, Mirabet V, Cobo AC, Escribá MJ, Simón C, et al. Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil Steril. 2010;93(1):268.e11–3. https://doi.org/10.1016/j.fertnstert.2009.09.046.CrossRef

74.

Fleury A, Pirello O, Maugard C, Mathelin C, Linck C. Breast cancer and ovarian tissue cryopreservation: review of the literature. J Gynaecol Obstet Hum Reprod. 2018;47(8):351–7. https://doi.org/10.1016/j.jogoh.2018.05.008.CrossRef

75.

Gellert SE, Pors SE, Kristensen SG, Bay-Bjorn AM, Ernst E, Yding Andersen C. Transplantation of frozen-thawed ovarian tissue: an update un worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Repr Genet. 2018;35(4):561–70. https://doi.org/10.1007/s10815-018-1144-2.CrossRef

76.

Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269–76. https://doi.org/10.1001/jama.2011.991.CrossRefPubMed

77.

Lambertini M, Moore HC, Leonard RCF, Loibl S, Munster PN, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton SE, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge A, Del Mastro L. Abstract GS4-01: pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients. Cancer Res, 2018; 78 (4 Supplement). https://doi.org/10.1158/1538-7445.SABCS17-GS4-01.

78.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32. https://doi.org/10.1056/NEJMoa1413204.CrossRefPubMedPubMedCentral

79.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG Intergroup S0230. JNCI J Natl Cancer Inst. 2019;111(2):210–3. https://doi.org/10.1093/jnci/djy185.CrossRefPubMed

80.

van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JS, van Santbrink EJ, et al. Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA. 2016;316(3):300–12. https://doi.org/10.1001/jama.2016.9389.CrossRefPubMed

81.

Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. The Lancet. 1999;354(9190):1586–90. https://doi.org/10.1016/s0140-6736(99)05203-4.CrossRef

82.

Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril. 2014;102(2):488–95 e483. https://doi.org/10.1016/j.fertnstert.2014.05.017.CrossRefPubMed

83.

Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol. 2013;29(11):993–6. https://doi.org/10.3109/09513590.2013.819083.CrossRefPubMed

84.

Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885–90. https://doi.org/10.1210/jc.2006-0962.CrossRefPubMed

85.

Dahhan T, Balkenende EME, Van Wely M, Linn SC, Goddijn M. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. The Cochrane Library, 2013 (11).

86.

Dahhan T, Balkenende EME, Beerendonk CCM, Fleischer K, Stoop D, Bos AME, et al. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: alternative versus standard stimulation protocols; the study protocol of the STIM-trial. Contemp Clin Trials. 2017;61:96–100. https://doi.org/10.1016/j.cct.2017.07.009.CrossRefPubMed

87.

Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033–45. https://doi.org/10.1093/humrep/dex027.CrossRefPubMed

88.

Shapira M, Raanani H, Meirow D. IVF for fertility preservation in breast cancer patients—efficacy and safety issues. Journal of Assisted Reproduction and Genetics. 2015;32(8):1171–8. https://doi.org/10.1007/s10815-015-0519-x.CrossRefPubMedPubMedCentral

89.

Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5. https://doi.org/10.1200/JCO.2007.14.8700.CrossRefPubMed

90.

Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73–9. https://doi.org/10.1200/JCO.2012.44.2285.CrossRefPubMed

91.

Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48(18):3355–77. https://doi.org/10.1016/j.ejca.2012.10.004.CrossRefPubMed

92.

Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, et al. Pregnancy after breast cancer: if you wish, ma’am. Breast Cancer Res Treat. 2011;129(2):309–17. https://doi.org/10.1007/s10549-011-1643-7.CrossRefPubMed

93.

Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer--a population-based cohort study from Sweden. PLoS Med. 2006;3(9):e336. https://doi.org/10.1371/journal.pmed.0030336.CrossRefPubMedPubMedCentral

94.

Langagergaard V. Birth outcome in women with breast cancer, cutaneous malignant melanoma, or Hodgkin’s disease: a review. Clin Epidemiol. 2010;3:7–19. https://doi.org/10.2147/CLEP.S12190.CrossRefPubMedPubMedCentral

95.

Black KZ, Nichols HB, Eng E, Rowley DL. Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study. Breast Cancer Res. 2017;19(11):1–8. https://doi.org/10.1186/s13058-017-0803-z.CrossRef

96.

Malone KE, Daling JR, Neal C, Suter NM, O’Brien C, Cushing-Haugen K, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000;88(6):1393–402.CrossRef

97.

National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk assessment: breast and ovarian. NCCN Guidelines, 2019. https://NCCN.org. Accessed 11 February 2019.

98.

Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. European Journal of Cancer. 2002;38:15–7.CrossRef

99.

Derks-Smeets IAP, de Die-Smulders CEM, Mackens S, van Golde R, Paulussen AD, Dreesen J, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of pre-implantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. Breast Cancer Res Treatment. 2014;145(3):673–81. https://doi.org/10.1007/s10549-014-2951-5.CrossRef

100.

Vriens IJH, Butalid ME, Schepers van der Sterren EE, van der Poel MH, Jansen-Engelen SL, van Riel AMM, van de Wouw YJ, Vriens B, van Haaren ER, Lemaire BM, Dercksen WW, Luiten EJ, De Boer M, De Die-Smulders CE, Derhaag JG, Van Golde R, Tjan-Heijnen VC (2017) Abstract PD6-03: Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience. Cancer Research 77 (4 Supplement). https://doi.org/10.1158/1538-7445.SABCS16-PD6-03

101.

Donnelly LS, Watson M, Moynihan C, Bancroft E, Evans DG, Eeles R, et al. Reproductive decision-making in young female carriers of a BRCA mutation. Hum Reprod. 2013;28(4):1006–12. https://doi.org/10.1093/humrep/des441.CrossRefPubMed

102.

Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2018;33(2):181–7. https://doi.org/10.1093/humrep/dex356.CrossRefPubMed

103.

Derks-Smeets I, Schrijver LH, De Die-Smulders CE, Tjan-Heijnen VC, Van Golde R, Smits L, et al. Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. Br J Cancer. 2018;1:357–63. https://doi.org/10.1038/s41416-018-0139-1.CrossRef

104.

Oktay K, Turan V, Titus S, Stobezki R, Liu L. BRCA Mutations, DNA Repair Deficiency, and Ovarian Aging. Biol Reprod. 2015;93(3):67. https://doi.org/10.1095/biolreprod.115.132290.CrossRefPubMedPubMedCentral

105.

Titus S. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Translat Med. 2013;5(172):1–12.CrossRef

106.

Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652–9. https://doi.org/10.1002/cncr.27952.CrossRefPubMedPubMedCentral

107.

Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet. 2017;34(11):1475–82. https://doi.org/10.1007/s10815-017-1014-3.CrossRefPubMedPubMedCentral

Title: Counseling young women with early breast cancer on fertility preservation
Authors: M. E. (Elena) ter Welle-Butalid
I. J. H. (Ingeborg) Vriens
J. G. (Josien) Derhaag
E. M. (Edward) Leter
C. E. (Christine) de Die-Smulders
M. (Marjolein) Smidt
R. J. T. (Ron) van Golde
V. C. G. (Vivianne) Tjan-Heijnen
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Fertility
Breast Cancer
Breast Cancer
Cytostatic Therapy
Tamoxifen
Published in: Journal of Assisted Reproduction and Genetics / Issue 12/2019
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-019-01615-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Counseling young women with early breast cancer on fertility preservation

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2019

Less-invasive chromosome screening of embryos and embryo assessment by genetic studies of DNA in embryo culture medium

Screening of triploid with low-coverage whole-genome sequencing by a single-nucleotide polymorphism-based test in miscarriage tissue

Analysis of molecular cytogenetic features and PGT-SR for two infertile patients with small supernumerary marker chromosomes

Density gradient centrifugation and swim-up for ICSI: useful, unsafe, or just unsuitable?

Association of UHRF1 gene polymorphisms with oligospermia in Chinese males

A rare frameshift variant in trans with the IVS9-5T allele of CFTR in a Chinese pedigree with congenital aplasia of vas deferens